MedPath

Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancer

Phase 1
Conditions
unresectable or recurrent gastric cancer
Registration Number
JPRN-UMIN000004729
Lead Sponsor
School of Medicine, Keio University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) with heart disease needed to treat (ex. ischemic cardiac disease, arrhythmia) Left ventricular hypertrophy according to high blood pressure, slight left ventricle load, slight right bundle branch block are acceptable. 2) Cardiac infarction that developed within six months 3) Cirrhosis and hepatitis of briskness 4) Breathing difficulties that require oxygen administration by interstitial pneumonia and lungs fiber syndrome, etc. 5) Gut freshness hemorrhage that repeatedly requires transfusion 6) with clinically important mental disorder need to treat or treating with mind drug 7) with uncontrollable diabetes mellitus 8) with intestinal obstruction and sub-intestinal obstruction 9) infection with fever or doubt it 10) Double cancer of briskness 11) brain metastasis with symptom 12) Acute inflammatory disorder 13) Peripheral neuropathy 14) history of severe drug anaphylaxis 15) history of severe anaphylaxis to drug included Cremohor EL or Stiffening castor oil 16) pregnant woman, breast-feeding woman, and possibility of pregnancy 17) doctor's decision not to be registered to this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath